FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CLEVELAND, Feb. 15, 2018 -- IMARC Research, a contract research organization based in Strongsville, Ohio, recently expanded its footprint in the medical device market by opening a new office in Minnetonka, Minn. The new office, located at 12301 Whitewater Drive, Suite 125, will continue to be managed by IMARC Senior Clinical Research Specialist Jim Moat.
IMARC opened its first Minneapolis office in the area in 2016. Having a second location continues IMARC’s office-based model, while providing increased flexibility for travel throughout the US and Canada. The move to a new office not only allows room for more staff, it will give the team space to host meetings with clients and potential clients.
The new office underscores IMARC’s continued growth and commitment to ensuring compliance for medical device research.
“Minneapolis is a strong medical device market, so this new location will allow us to better serve our current clients and develop exciting new partnerships,” IMARC CEO and President Sandra Maddock said. “We are eager to assist in advancing clinical research by bringing cost-effective monitoring, managing data safety monitoring boards and clinical events committees, auditing, training, project management and other services closer to home for researchers in this area.”
Moat is a Certified Clinical Research Associate with more than 26 years of experience in medical device product development, with expertise in cardiology, obesity, orthopedic and stroke projects.
About IMARC Research:
A privately held company located in Strongsville, Ohio, IMARC assists the clinical research community in the pursuit of FDA and worldwide approvals. IMARC is a medical device CRO whose effectiveness is built on our commitment to human subject protection and our dedication to ensuring study compliance in our partnership with clients. IMARC’s approach – based solidly in both U.S. and international regulations – results in the support, proof and assurance researchers seek to overcome chaos caused by complexity, while achieving compliance through consistency. Providing committed, competent and confident consultation is how IMARC sets the highest standards for site outcomes and study partnerships.
More information is available at http://www.imarcresearch.com.
Media Contact
John Lehmann
Director of Business Development
440-801-1540, ext. 209
[email protected]
